Phosplatin Therapeutics is a clinical stage pharmaceutical company developing phosphaplatins, a family of rationally designed small molecules for the treatment of cancer.

The phosphaplatin family of compounds is the result of over twenty years of investigation. The lead agent, PT-112, is a first-in-class platinum-pyrophosphate conjugate that combines immunogenic and apoptotic properties in combating cancer, along with an exceptional tolerability profile. It was rationally designed to avoid the toxicity and drug resistance mechanisms of conventional chemotherapy.  its unique properties may allow PT-112 to be effective in indications crossing solid tumors and hematological malignancies.


Since inception, the company has built a robust data package through a variety of investigations of these novel compounds. Our collaborations with pharmaceutical partners, universities and contract research organizations range across thirteen countries.

The ongoing Phase I study of PT-112 is led by the investigational cancer therapeutics group at the MD Anderson Cancer Center in Houston, Texas, along with three other U.S. sites, and was the subject of a presentation and peer-review oral discussion at the asco 2017 annual meeting.

Under a collaborative agreement with SciClone Pharmaceuticals for rights in China and Vietnam, PT-112 is also the subject of a Phase i / ii combination study recently launched in taiwan.

Our aim is to bring these agents to the market as quickly as possible, providing a safe, effective and affordable new therapy to cancer patients around the world.